© 1996 Oxford University Press
other |
Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver puptative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats
Istituto di Patologia Generale e Centro di Ricerche Oncologiche, Universita di Sassari Via P. Manzella 4, 07100, Sassari
1Dipartimento di Biomedicina, Sezione di Patologia Generale, Universita di Pisa Italy
2To whom correspondence should be addressed
S-Adenosyl-L-methionine (SAM) is a strong chemo-preventive agent of rat liver carcinogenesis. Examination was made to determine whether inhibition by SAM of the development of preneoplastic liver lesions persists to SAM withdrawal in diethylnitrosamine-initiated F344 rats promoted with thiobenzamide (TB). The rats were subjected, 2 weeks after initiation, to 5 weeks feeding with a 0.1% TB diet followed by a TB-free diet for 6 weeks and then by a second TB treatment for 3 weeks. SAM (384 µmol/kg/day) was injected i.m. during the first TB cycle (treatment A) or for 6 weeks after the first TB cycle (treatment B). Many
-glutamyltranspeptidase (GGT)-positive lesions developed in initiated rats after the first TB cycle. They decreased in number after TB withdrawal, while partial recovery of lesion number and a great increase in volume occurred after the second TB cycle. Liver ornithine decarboxylase (ODC) activity and c-myc and c-Ha-ras mRNAs increased during the TB cycle. Liver ornithine decarboxylase (ODC) activity and c-myc and c-Ha-ras mRNAs increased during the TB cycles and returned to normal liver values after TB withdrawal. Number and size of GGT-positive lesions, DNA synthesis of GGT-positive cells, liver ODC activity and c-myc and c-Ha-ras mRNA levels decreased as a consequence of SAM treatment A. The recovery of these parameters, induced by a second TB cycle in rats not treated with SAM, was prevented by SAM treatment B. These results suggest that SAM causes a persistent decrease in growth capacity of preneoplastic liver lesions in rats subjected to a diethylnitrosamine/TB protocol.